BMAC vs Triamcinolone for Hip Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial compares two treatments for hip osteoarthritis: one that uses the patient's own bone marrow cells to promote healing, and another that uses a steroid to quickly reduce inflammation. The study aims to determine which treatment offers better long-term pain relief and improved mobility.
Will I have to stop taking my current medications?
Yes, you will need to stop taking pain and anti-inflammatory medications two weeks before the trial starts.
Is Triamcinolone safe for treating osteoarthritis?
Triamcinolone acetonide, used in various forms for osteoarthritis, is generally well tolerated with a safety profile similar to placebo and other forms of triamcinolone. It is designed to reduce systemic exposure, which helps lessen common steroid-related side effects like blood sugar increases.12345
How does the drug triamcinolone acetonide differ from other treatments for hip osteoarthritis?
Triamcinolone acetonide is a corticosteroid that can be injected directly into the hip joint to reduce inflammation and pain, offering a targeted approach compared to oral medications. The extended-release form provides longer-lasting relief, which may reduce the frequency of injections needed.12356
Who Is on the Research Team?
Carlos Higuera-Rueda, MD
Principal Investigator
Cleveland Clinic Florida
Leonardo Oliveira, MD
Principal Investigator
Cleveland Clinic Florida
Are You a Good Fit for This Trial?
This trial is for men and women aged 18-65 with hip osteoarthritis, who have had physical therapy but no recent corticosteroid injections or active autoimmune diseases. Participants must not be pregnant, planning pregnancy, or have a history of certain medical conditions like uncontrolled diabetes or thyroid dysfunction.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a bone marrow aspirate concentrate (BMAC) injection or a triamcinolone injection under ultrasound guidance
Initial Follow-up
Participants are monitored for safety and effectiveness at 6 weeks post-procedure
Extended Follow-up
Participants are monitored for changes in pain and functional scores at 3 months, 6 months, and 12 months post-procedure
What Are the Treatments Tested in This Trial?
Interventions
- Emcyte PureBMC
- Triamcinolone
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor
Lisa Dean Moseley Foundation
Collaborator